Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas.

Abstract

Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.

• Authors: Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder, Marc Ladanyi
• Journal: Sarcoma (Sarcoma) Vol. 2021 Pg. 5575444 ( 2021) ISSN: 1357-714X [Print] Egypt
• PMID: 34349608 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Jun Wang et al.